

PROGRAMME

TO REGISTER:

http://go.usa.gov/cm4um

THE 10TH SICKLE CELL IN FOCUS 2 - 3 JUNE 2016 CONFERENCE



Natcher Conference Center
National Heart, Lung and Blood Institute (NHLBI)
National Institutes of Health (NIH)
Bethesda, near Washington DC, USA

Co-hosted by the National Heart, Lung and Blood Institute and the South Thames Sickle Cell & Thalassaemia Network, this two-day, intensive, educational conference highlights and discusses emerging clinical complications and management of sickle cell disease.

The clinical and scientific lectures are aimed at consultants, trainee doctors, healthcare professionals involved in the care of patients with sickle cell disease, plus academic researchers in this field.

For more information and to register online for free:

http://go.usa.gov/cm4um or www.ststn.co.uk/scif/scif2016/





THURSDAY, 2 JUNE

Natcher Conference Center



SESSION ONE: SICKLE CELL DISEASE - A GLOBAL HEALTH ISSUE

Chairs: Kwaku Ohene-Frempong / Norma Lerner

United States of America:

Kathy Hassell

University of Colorado, USA

Europe:

Beatrice Gulbis

Hôpital Erasme, Belgium

Africa: Dapa Diallo

University of Bamako, Mali

The Caribbean: Jennifer Knight

University Hospital of the West Indies, Jamaica

India:

Brazil:

Roshan B. Colah

Hemominas Foundation, Brazil

Anna Proietti

National Institute of Immunohaematology,

India

SESSION TWO: SICKLE CELL DISEASE AND MALARIA - MORE THAN JUST A BALANCING ACT

Chair: Bill Eaton

Protective role of HbS and other red blood cell defects on malaria: Tom Williams

Imperial College London, UK \ KEMRI-Wellcome Trust Collaborative Programme, Kilifi, Kenya The impact of iron availability on malaria and sickle cell disease severity:

Hans Áckerman

National Heart, Lung and Blood Institute, National Institutes of Health, USA A microfluidic platform to assess malaria and sickle stickiness:

Subra Suresh

Carnegi Mellon University, Pittsburgh, USA

SESSION THREE: VASCULAR INJURY & INFLAMMATION IN SICKLE CELL DISEASE

Chair: Alan Schechter

Inflammasomes in health and disease:

Fayyaz Sutterwala

University of Iowa, USA

TLRs, inflammation and sickle cell disease - the innate connection:

John Belcher

University of Minnesota, USA

Drivers of inflammation in sickle cell

disease - role of neutrophils:

Dachuan Zhang

Albert Einstein College of Medicine, USA

SESSION FOUR: UPDATES Chair: (TBC)

Newborn screening and point-ofcare testing in developing countries:

Carolyn Hoppe

Children's Hospital & Research Center, USA Clinical trials: Deepa Manwani

The Children's Hospital at Montefiore, USA

Bone marrow transplant:

John Horan

Children's Healthcare of Atlanta, USA

SESSION FIVE: DEBATE

HSCT IS RECOMMENDED FOR SECONDARY PREVENTION OF CEREBROVASCULAR INFARCTS IN

SICKLE CELL DISEASE Chair: Oswaldo Castro

For:

Michael DeBaun

Vanderbilt University School of Medicine, USA

Against:

Elliott Vichinsky

Children's Hospital & Research Center, Oakland, USA







SESSION ONE: GENETICS & GENOMICS - PRIME TIME IN HEMOGLOBIN DISORDERS Chairs: David Bodine / Courtney Fitzhugh

Genetics and genomics in clinical studies –potentials and pitfalls: Steve Chanock

National Cancer Institute, National Institutes of Health, USA

Impact of genetics and genomics in sickle cell disease: Swee Lay Thein

National Heart, Lung and Blood Institute, National Institutes of Health, USA Gene therapy: John Tisdale

National Heart, Lung and Blood Institute, National Institutes of Health, USA

Application of genome editing in hemoglobin disorders: Dan Bauer

Children's Hospital Boston, USA

Environmental determinants of disease severity:
David Rees

King's College Hospital NHS Foundation Trust / King's College London, UK

SESSION TWO: UPDATES ON MANAGEMENT - PART ONE Chair: Samir Ballas

Management of pain and opioid use in patients with sickle cell disease:

Patrick Carroll

Johns Hopkins University School of Medicine, USA

Inflammation and pain in sickle cell disease:

Deepika Darbari

Children's National Medical Center, USA

Causes, complications and management of hypoxia in sickle cell disease: Roberto Machado

University of Illinois College of Medicine at Chicago, USA

SESSION THREE: UPDATES ON MANAGEMENT - PART TWO
Chair: Paul Swerdlow

Expanding use of hydroxyurea in sickle cell disease:

Jane Hankins

St Jude Children's Research Hospital, USA

Blood transfusion, alloimmunization, and role of genotyping for variant antigens:

Stella Chou

The Children's Hospital of Philadelphia, USA

Coagulation activation in sickle cell

disease:

Kenneth Ataga

University of North Carolina, USA

SESSION FOUR: DEBATE
HIGH MORTALITY IN YOUNG ADULTS IS DUE TO THE BREAKDOWN IN TRANSITION TO ADULT CARE
Chair: Kathy Hassell

Yes:

Mariane de Montalembert

Necker-Enfants Malades Hospital, France

No:

Sophie Lanzkron

Johns Hopkins University School of Medicine, Baltimore, USA